+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets- Product Image
Central Nervous System (CNS) Biomarkers: Technologies and Global Markets- Product Image
New

Central Nervous System (CNS) Biomarkers: Technologies and Global Markets

  • PDF Icon

    Report

  • 172 Pages
  • February 2026
  • Region: Global
  • BCC Research
  • ID: 5783274
Description Jump to:
The Central Nervous System (CNS) Biomarkers Market was valued at USD 7.6 Billion in 2025, and is projected to reach USD 13.8 Billion by 2030, rising at a CAGR of 12.6%.

CNS biomarkers are transforming drug development through high-level technologies in machine learning (ML), natural language processing (NLP) and predictive analytics. These support every part of the R&D process, from the identification of patients and protocol design to site selection and real-time trial monitoring. CNS biomarkers reduce operational inefficiencies by facilitating faster data-driven decisions, minimizing human error and shortening development timelines, which are all crucial in accelerating the development of cost-effective oncology therapies.

AI-powered electronic health records (EHR) and genomic and wearable device output analysis could lead to better stratification of patients, better prognosis and improved medication strategies. This approach is necessary for oncology due to the heterogeneity of lesions and the specificity of treatments.

Report Scope

The report examines and segments the global central nervous system (CNS) biomarkers market by disease, application, technology and biomarker type. It also provides insights into emerging trends and potential growth drivers. The report focuses on Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson’s disease and others. By application, it examines drug discovery and development, clinical diagnostics and personalized medicine. By technology, proteomics, molecular imaging and genomics are reviewed. Finally, biomarker types such as amyloid-beta, tau protein and others are considered.

The report also provides an inclusive regional analysis covering North America, Europe, Asia-Pacific, South America and the Middle East and Africa. It evaluates the impact of AI adoption on the CNS biomarkers industry and market dynamics, including drivers, challenges and emerging trends, while highlighting innovations in product and performance enhancements. The study concludes with an analysis of major market participants and their offerings.

Global revenue ($ million) for the base year of 2024, estimates for 2025 and data for the forecast period 2025 through 2030 are also part of the report.

The report includes:

  • 141 data tables and 44 additional tables
  • An up-to-date overview and analysis of the global market for central nervous system (CNS) biomarkers
  • In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030, including projections of CAGRs through 2030
  • Analysis of market opportunities with a holistic review of Porter’s Five Forces model and industry supply chain analysis, considering both micro- and macro-environmental factors prevailing in the market
  • Explanation of market drivers, restraints and other forces impacting the global market
  • Discussion of CNS disease segments, prevalence and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, etc.
  • Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios
  • Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the practices of leading companies
  • Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
  • Profiles of the leading global companies, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Abbott and Bio-Rad Laboratories Inc.

Table of Contents

Chapter 1 Executive Summary
  • Market Outlook
  • Scope of Report
  • Market Summary
  • Market Dynamics and Growth Factors
  • Emerging Technologies
  • Segmental Analysis
  • Regional Analysis
  • Conclusion
Chapter 2 Market Overview
  • Current Market Overview
  • Outlook
  • Analysis of Macroeconomic Factors
  • Impact of U.S. Tariffs on the Market
  • Impact of the Ukraine-Russia War
  • Global Economic Stability and Supply Chains
  • Public and Private R&D Investment
  • Healthcare Expenditure and Economic Growth
  • Aging Population and Disease Burden
  • Porter's Five Forces Analysis
  • Bargaining Power of Buyers: Moderate to High
  • Bargaining Power of Suppliers: High
  • Potential for New Entrants: Moderate to Low
  • Threat of Substitute: Moderate
  • Competition in the Industry: High
Chapter 3 Market Dynamics
  • Market Dynamics Snapshot
  • Market Drivers
  • Prevalence of Neurological Disorders
  • Advances in Diagnostic Technologies and Research
  • Focus on Early Detection and Personalized Medicine
  • Market Restraints
  • High Cost of Advanced Diagnostic Assays
  • Regulatory and Validation Challenges
  • Limited Awareness and Adoption Among Healthcare Providers
  • Market Opportunities
  • Growth in Neurodegenerative Disease Research
  • Expansion of Early Diagnosis and Screening Programs
  • Integration with Personalized Medicine
Chapter 4 Regulatory Landscape
  • Regulatory Framework
  • U.S.
  • Europe
  • India
  • Australia
  • Japan
Chapter 5 Emerging Technologies and Patent Analysis
  • Overview
  • Emerging Technologies
  • High-Resolution Mass Spectrometry
  • Next-Generation Sequencing
  • Multiplexed Immunoassays
  • Single-Cell RNA Sequencing
  • Patent Analysis
  • Key Takeaways
  • Patents by Year
  • Patents by Leading Jurisdiction
  • Patents by Applicants
Chapter 6 Market Segmentation Analysis
  • Segmentation Breakdown
  • Global CNS Biomarkers Market, by Disease
  • Key Takeaways
  • Alzheimer's Disease
  • MS, ALS and FTD
  • Parkinson's Disease
  • Others
  • Global CNS Biomarkers Market, by Application
  • Key Takeaways
  • Drug Discovery and Development
  • Clinical Diagnostics
  • Personalized Medicine
  • Global CNS Biomarkers Market, by Technology
  • Key Takeaways
  • Proteomics
  • Molecular Imaging
  • Genomics
  • Global CNS Biomarkers Market, by Biomarker Type
  • Key Takeaways
  • Amyloid-Beta
  • Tau Protein
  • Others
  • Geographic Breakdown
  • Global CNS Biomarkers Market, by Region
  • Key Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • Middle East and Africa
  • South America
Chapter 7 Competitive Intelligence
  • Industry Structure
  • Company Market Share Analysis
  • Strategic Analysis
Chapter 8 Sustainability in the CNS Biomarkers Market: An ESG Perspective
  • Introduction to ESG
  • Sustainability Trends and Initiatives in the CNS Biomarkers Industry
  • Concluding Remarks
Chapter 9 Appendix
  • Methodology
  • Abbreviations
  • Company Profiles
  • ABBOTT
  • BIOMERIEUX
  • BIO-RAD LABORATORIES INC.
  • C2N DIAGNOSTICS
  • F. HOFFMANN-LA ROCHE LTD.
  • FUJIREBIO
  • LABCORP
  • LILLY USA LLC.
  • MERCK KGAA
  • QUANTERIX
  • QUEST DIAGNOSTICS INC.
  • REVVITY
  • SIEMENS HEALTHINEERS AG
  • SYSMEX CORP.
  • THERMO FISHER SCIENTIFIC INC.
  • Emerging Start-ups/Market Disruptors
List of Tables
Summary Table: Global Market for CNS Biomarkers, by Region, Through 2030
Table 1: Patents Granted for CNS Biomarkers, by Year, 2022-2025
Table 2: Patents Granted for CNS Biomarkers, by Top Jurisdiction, 2022-2025
Table 3: Patents Granted for CNS Biomarkers, by Applicants, 2022-2025
Table 4: Global Market for CNS Biomarkers, by Disease, Through 2030
Table 5: Global Market for Alzheimer’s Disease in CNS Biomarkers, by Region, Through 2030
Table 6: Global Market for MS, ALS and FTD in CNS Biomarkers, by Region, Through 2030
Table 7: Global Market for Parkinson’s Disease in CNS Biomarkers, by Region, Through 2030
Table 8: Global Market for Other Diseases in CNS Biomarkers, by Region, Through 2030
Table 9: Global Market for CNS Biomarkers, by Application, Through 2030
Table 10: Global Market for CNS Biomarkers for Drug Discovery and Development, by Region, Through 2030
Table 11: Global Market for CNS Biomarkers for Clinical Diagnostics, by Region, Through 2030
Table 12: Global Market for CNS Biomarkers for Personalized Medicine, by Region, Through 2030
Table 13: Global Market for CNS Biomarkers, by Technology, Through 2030
Table 14: Global Market for Proteomic Biomarkers, by Region, Through 2030
Table 15: Global Market for Molecular Imaging in CNS Biomarkers, by Region, Through 2030
Table 16: Global Market for Genomic Biomarkers, by Region, Through 2030
Table 17: Global Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 18: Global Market for Amyloid-Beta Biomarkers, by Region, Through 2030
Table 19: Global Market for Tau Protein Biomarkers, by Region, Through 2030
Table 20: Global Market for Other CNS Biomarkers, by Region, Through 2030
Table 21: Global Market for CNS Biomarkers, by Region, Through 2030
Table 22: North American Market for CNS Biomarkers, by Disease, Through 2030
Table 23: North American Market for CNS Biomarkers, by Application, Through 2030
Table 24: North American Market for CNS Biomarkers, by Technology, Through 2030
Table 25: North American Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 26: North American Market for CNS Biomarkers, by Country, Through 2030
Table 27: U.S. Market for CNS Biomarkers, by Disease, Through 2030
Table 28: U.S. Market for CNS Biomarkers, by Application, Through 2030
Table 29: U.S. Market for CNS Biomarkers, by Technology, Through 2030
Table 30: U.S. Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 31: Canadian Market for CNS Biomarkers, by Disease, Through 2030
Table 32: Canadian Market for CNS Biomarkers, by Application, Through 2030
Table 33: Canadian Market for CNS Biomarkers, by Technology, Through 2030
Table 34: Canadian Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 35: Mexican Market for CNS Biomarkers, by Disease, Through 2030
Table 36: Mexican Market for CNS Biomarkers, by Application, Through 2030
Table 37: Mexican Market for CNS Biomarkers, by Technology, Through 2030
Table 38: Mexican Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 39: Prevalence of Dementia in Europe, by Age Group and Sex, 2025
Table 40: European Market for CNS Biomarkers, by Disease, Through 2030
Table 41: European Market for CNS Biomarkers, by Application, Through 2030
Table 42: European Market for CNS Biomarkers, by Technology, Through 2030
Table 43: European Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 44: European Market for CNS Biomarkers, by Country, Through 2030
Table 45: German Market for CNS Biomarkers, by Disease, Through 2030
Table 46: German Market for CNS Biomarkers, by Application, Through 2030
Table 47: German Market for CNS Biomarkers, by Technology, Through 2030
Table 48: German Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 49: U.K. Market for CNS Biomarkers, by Disease, Through 2030
Table 50: U.K. Market for CNS Biomarkers, by Application, Through 2030
Table 51: U.K. Market for CNS Biomarkers, by Technology, Through 2030
Table 52: U.K. Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 53: French Market for CNS Biomarkers, by Disease, Through 2030
Table 54: French Market for CNS Biomarkers, by Application, Through 2030
Table 55: French Market for CNS Biomarkers, by Technology, Through 2030
Table 56: French Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 57: Italian Market for CNS Biomarkers, by Disease, Through 2030
Table 58: Italian Market for CNS Biomarkers, by Application, Through 2030
Table 59: Italian Market for CNS Biomarkers, by Technology, Through 2030
Table 60: Italian Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 61: Spanish Market for CNS Biomarkers, by Disease, Through 2030
Table 62: Spanish Market for CNS Biomarkers, by Application, Through 2030
Table 63: Spanish Market for CNS Biomarkers, by Technology, Through 2030
Table 64: Spanish Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 65: Rest of Europe Market for CNS Biomarkers, by Disease, Through 2030
Table 66: Rest of Europe Market for CNS Biomarkers, by Application, Through 2030
Table 67: Rest of Europe Market for CNS Biomarkers, by Technology, Through 2030
Table 68: Rest of Europe Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 69: Asia-Pacific Market for CNS Biomarkers, by Disease, Through 2030
Table 70: Asia-Pacific Market for CNS Biomarkers, by Application, Through 2030
Table 71: Asia-Pacific Market for CNS Biomarkers, by Technology, Through 2030
Table 72: Asia-Pacific Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 73: Asia-Pacific Market for CNS Biomarkers, by Country, Through 2030
Table 74: Chinese Market for CNS Biomarkers, by Disease, Through 2030
Table 75: Chinese Market for CNS Biomarkers, by Application, Through 2030
Table 76: Chinese Market for CNS Biomarkers, by Technology, Through 2030
Table 77: Chinese Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 78: Japanese Market for CNS Biomarkers, by Disease, Through 2030
Table 79: Japanese Market for CNS Biomarkers, by Application, Through 2030
Table 80: Japanese Market for CNS Biomarkers, by Technology, Through 2030
Table 81: Japanese Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 82: Indian Market for CNS Biomarkers, by Disease, Through 2030
Table 83: Indian Market for CNS Biomarkers, by Application, Through 2030
Table 84: Indian Market for CNS Biomarkers, by Technology, Through 2030
Table 85: Indian Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 86: South Korean Market for CNS Biomarkers, by Disease, Through 2030
Table 87: South Korean Market for CNS Biomarkers, by Application, Through 2030
Table 88: South Korean Market for CNS Biomarkers, by Technology, Through 2030
Table 89: South Korean Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 90: Australian Market for CNS Biomarkers, by Disease, Through 2030
Table 91: Australian Market for CNS Biomarkers, by Application, Through 2030
Table 92: Australian Market for CNS Biomarkers, by Technology, Through 2030
Table 93: Australian Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 94: Rest of Asia-Pacific Market for CNS Biomarkers, by Disease, Through 2030
Table 95: Rest of Asia-Pacific Market for CNS Biomarkers, by Application, Through 2030
Table 96: Rest of Asia-Pacific Market for CNS Biomarkers, by Technology, Through 2030
Table 97: Rest of Asia-Pacific Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 98: MEA Market for CNS Biomarkers, by Disease, Through 2030
Table 99: MEA Market for CNS Biomarkers, by Application, Through 2030
Table 100: MEA Market for CNS Biomarkers, by Technology, Through 2030
Table 101: MEA Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 102: MEA Market for CNS Biomarkers, by Country, Through 2030
Table 103: Middle East Market for CNS Biomarkers, by Disease, Through 2030
Table 104: Middle East Market for CNS Biomarkers, by Application, Through 2030
Table 105: Middle East Market for CNS Biomarkers, by Technology, Through 2030
Table 106: Middle East Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 107: African Market for CNS Biomarkers, by Disease, Through 2030
Table 108: African Market for CNS Biomarkers, by Application, Through 2030
Table 109: African Market for CNS Biomarkers, by Technology, Through 2030
Table 110: African Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 111: South American Market for CNS Biomarkers, by Disease, Through 2030
Table 112: South American Market for CNS Biomarkers, by Application, Through 2030
Table 113: South American Market for CNS Biomarkers, by Technology, Through 2030
Table 114: South American Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 115: South American Market for CNS Biomarkers, by Country, Through 2030
Table 116: Brazilian Market for CNS Biomarkers, by Disease, Through 2030
Table 117: Brazilian Market for CNS Biomarkers, by Application, Through 2030
Table 118: Brazilian Market for CNS Biomarkers, by Technology, Through 2030
Table 119: Brazilian Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 120: Argentine Market for CNS Biomarkers, by Disease, Through 2030
Table 121: Argentine Market for CNS Biomarkers, by Application, Through 2030
Table 122: Argentine Market for CNS Biomarkers, by Technology, Through 2030
Table 123: Argentine Market for CNS Biomarkers, by Biomarker Type, Through 2030
Table 124: Rest of South America Market for CNS Biomarkers, by Disease, Through 2030
Table 125: Rest of South America Market for CNS Biomarkers, by Application, Through 2030
Table 126: Rest of South America Market for CNS Biomarkers, by Technology, Through 2030
Table 127: Rest of South America Market for CNS Biomarkers, by Biomarker Type,Through 2030
Table 128: Strategic Initiatives for CNS Biomarkers Market, 2024 and 2025
Table 129: Abbreviations Used in the Global CNS Biomarkers Market Report
Table 130: Abbott: Company Snapshot
Table 131: Abbott: Financial Performance, FY 2023 and 2024
Table 132: Abbott: Product Portfolio
Table 133: Abbott: News/Key Developments, 2023 and 2024
Table 134: bioMérieux: Company Snapshot
Table 135: bioMérieux: Financial Performance, FY 2023 and 2024
Table 136: bioMérieux: Product Portfolio
Table 137: bioMérieux: News/Key Developments, 2023 and 2024
Table 138: Bio-Rad Laboratories Inc.: Company Snapshot
Table 139: Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024
Table 140: Bio-Rad Laboratories Inc.: Product Portfolio
Table 141: Bio-Rad Laboratories Inc.: News/Key Developments, 2024 and 2025
Table 142: C2N Diagnostics: Company Snapshot
Table 143: C2N Diagnostics: Product Portfolio
Table 144: C2N Diagnostics: News/Key Developments, 2022-2025
Table 145: F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 146: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 147: F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 148: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
Table 149: Fujirebio: Company Snapshot
Table 150: Fujirebio: Product Portfolio
Table 151: Fujirebio: News/Key Developments, 2023-2025
Table 152: Labcorp: Company Snapshot
Table 153: Labcorp: Financial Performance, FY 2023 and 2024
Table 154: Labcorp: Product Portfolio
Table 155: Labcorp: News/Key Developments, 2024 and 2025
Table 156: Lilly USA LLC.: Company Snapshot
Table 157: Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 158: Lilly USA LLC.: Product Portfolio
Table 159: Merck KGaA: Company Snapshot
Table 160: Merck KGaA: Financial Performance, FY 2023 and 2024
Table 161: Merck KGaA: Product Portfolio
Table 162: Merck KGaA: News/Key Developments, 2024
Table 163: Quanterix: Company Snapshot
Table 164: Quanterix: Financial Performance, FY 2023 and 2024
Table 165: Quanterix: Product Portfolio
Table 166: Quanterix: News/Key Developments, 2025
Table 167: Quest Diagnostics Inc.: Company Snapshot
Table 168: Quest Diagnostics Inc.: Financial Performance, FY 2023 and 2024
Table 169: Quest Diagnostics Inc.: Product Portfolio
Table 170: Revvity: Company Snapshot
Table 171: Revvity: Financial Performance, FY 2023 and 2024
Table 172: Revvity: Product Portfolio
Table 173: Siemens Healthineers AG: Company Snapshot
Table 174: Siemens Healthineers AG: Financial Performance, FY 2023 and 2024
Table 175: Siemens Healthineers AG: Product Portfolio
Table 176: Siemens Healthineers AG: News/Key Developments, 2024 and 2025
Table 177: Sysmex Corp.: Company Snapshot
Table 178: Sysmex Corp.: Financial Performance, FY 2023 and 2024
Table 179: Sysmex Corp.: Product Portfolio
Table 180: Thermo Fisher Scientific Inc.: Company Snapshot
Table 181: Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
Table 182: Thermo Fisher Scientific Inc.: Product Portfolio
Table 183: Thermo Fisher Scientific Inc.: News/Key Developments, 2025
Table 184: List of a Few Emerging Startups
List of Figures
Summary Figure: Global Market Share for CNS Biomarkers, by Region, 2024
Figure 1: Porter’s Five Forces Analysis: CNS Biomarkers Market
Figure 2: Market Dynamics of CNS Biomarkers
Figure 3: Global Market Share for CNS Biomarkers, by Disease, 2024
Figure 4: Global Market Share for Alzheimer’s Disease in CNS Biomarkers, by Region, 2024
Figure 5: Global Market Share for MS, ALS and FTD in CNS Biomarkers, by Region, 2024
Figure 6: Global Market Share for Parkinson’s Disease in CNS Biomarkers, by Region, 2024
Figure 7: Global Market Share for Other Diseases in CNS Biomarkers, by Region, 2024
Figure 8: Global Market Share for CNS Biomarkers, by Application, 2024
Figure 9: Global Market Share for CNS Biomarkers for Drug Discovery and Development, by Region, 2024
Figure 10: Global Market Share for CNS Biomarkers for Clinical Diagnostics, by Region, 2024
Figure 11: Global Market Share for CNS Biomarkers for Personalized Medicine, by Region, 2024
Figure 12: Global Market Share for CNS Biomarkers, by Technology, 2024
Figure 13: Global Market Share for Proteomic Biomarkers, by Region, 2024
Figure 14: Global Market Share for Molecular Imaging in CNS Biomarkers, by Region, 2024
Figure 15: Global Market Share for Genomic Biomarkers, by Region, 2024
Figure 16: Global Market Share for CNS Biomarkers, by Biomarker Type, 2024
Figure 17: Global Market Share for Amyloid-beta Biomarkers, by Region, 2024
Figure 18: Global Market Share for Tau Protein Biomarkers, by Region, 2024
Figure 19: Global Market Share for Other CNS Biomarkers, by Region, 2024
Figure 20: Global Market Share for CNS Biomarkers, by Region, 2024
Figure 21: North American Market Share for CNS Biomarkers, by Country, 2024
Figure 22: European Market Share for CNS Biomarkers, by Country, 2024
Figure 23: Asia-Pacific Market Share for CNS Biomarkers, by Country, 2024
Figure 24: MEA Market Share for CNS Biomarkers, by Country, 2024
Figure 25: South American Market Share for CNS Biomarkers, by Country, 2024
Figure 26: Global Market Share for CNS Biomarkers, by Leading Companies, FY 2024
Figure 27: Abbott: Revenue Share, by Business Unit, FY 2024
Figure 28: Abbott: Revenue Share, by Country/Region, FY 2024
Figure 29: bioMérieux: Revenue Share, by Business Unit, FY 2024
Figure 30: bioMérieux: Revenue Share, by Country/Region, FY 2024
Figure 31: Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024
Figure 32: Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024
Figure 33: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
Figure 34: F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
Figure 35: Labcorp: Revenue Share, by Business Unit, FY 2024
Figure 36: Labcorp: Revenue Share, by Country/Region, FY 2024
Figure 37: Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
Figure 38: Merck KGaA: Revenue Share, by Business Unit, FY 2024
Figure 39: Merck KGaA: Revenue Share, by Country/Region, FY 2024
Figure 40: Quanterix: Revenue Share, by Business Unit, FY 2024
Figure 41: Quanterix: Revenue Share, by Country/Region, FY 2024
Figure 42: Quest Diagnostics Inc.: Revenue Share, by Business Unit, FY 2024
Figure 43: Revvity: Revenue Share, by Business Unit, FY 2024
Figure 44: Revvity: Revenue Share, by Country/Region, FY 2024
Figure 45: Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2024
Figure 46: Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2024
Figure 47: Sysmex Corp.: Revenue Share, by Country/Region, FY 2024
Figure 48: Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2024
Figure 49: Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2024

Companies Mentioned

  • Abbott
  • Biomerieux
  • Bio-Rad Laboratories Inc.
  • C2N Diagnostics
  • F. Hoffmann-La Roche Ltd.
  • Fujirebio
  • Labcorp
  • Lilly Usa LLC.
  • Merck KGaA
  • Quanterix
  • Quest Diagnostics Inc.
  • Revvity
  • Siemens Healthineers AG
  • Sysmex Corp.
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages172
PublishedFebruary 2026
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 7.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 13.8 Billion
Compound Annual Growth Rate12.6%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Central Nervous System Biomarkers - Global Strategic Business Report - Product Image

Central Nervous System Biomarkers - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
Global Central Nervous System Biomarkers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Central Nervous System Biomarkers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 115 Pages
  • Global
From
Central Nervous System Biomarkers Market Report 2026 - Product Image

Central Nervous System Biomarkers Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Central Nervous System Biomarkers Market - Global Forecast 2026-2032 - Product Image

Central Nervous System Biomarkers Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Biomarker Technologies Market Report by Test Type, Indication, Product, Technology, Application, and Region 2025-2033 - Product Image

Biomarker Technologies Market Report by Test Type, Indication, Product, Technology, Application, and Region 2025-2033

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.